Navigation Links
Regeneron Reports First Quarter 2011 Financial and Operating Results
Date:5/3/2011

TARRYTOWN, N.Y., May 3, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2011 and provided an update on development programs and upcoming milestones.  

Clinical Programs UpdateVEGF Trap-Eye (aflibercept ophthalmic solution)– Ophthalmologic DiseasesVEGF Trap-Eye is a fusion protein locally administered in the eye that is designed to bind Vascular Endothelial Growth Factor-A (VEGF-A) and Placental Growth Factor (PlGF), proteins that are involved in the abnormal growth of new blood vessels.  Regeneron maintains exclusive rights to VEGF Trap-Eye in the United States.  Bayer HealthCare LLC has rights to market VEGF Trap-Eye outside the U.S., where the companies will share equally in profits from any future sales of VEGF Trap-Eye.

In February 2011, Regeneron submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD).  In April 2011, the FDA accepted the BLA for filing and granted the Company's request for Priority Review.  Under Priority Review, the target date for an FDA decision on the VEGF Trap-Eye BLA is August 20, 2011.

Also in February 2011, data from the Phase 3 VIEW 1 and VIEW 2 trials of VEGF Trap-Eye in patients with wet AMD and the Phase 3 COPERNICUS trial in macular edema due to central retinal vein occlusion (CRVO) were presented at the Bascom Palmer Eye Institute's Angiogenesis, Exudation and Degeneration 2011 meeting. Results of the Phase 2 DA VINCI trial of VEGF Trap-Eye in diabetic macular edema (DME) were also presented.

In April 2011, Regeneron and Bayer HealthCare announced positive top-line results for VEGF Trap-Eye in the Phase 3 GALILEO study in patients with macular edema due to CRVO.
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Regeneron Announces Presentation at the Bank of America Merrill Lynch 2011 Health Care Conference
2. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion
3. Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
4. Regeneron Announces Presentation at the 10th Annual Needham Healthcare Conference
5. Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer
6. Regeneron Announces March 2011 Investor Conference Presentations
7. Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment of Wet Age-Related Macular Degeneration
8. Regeneron Reports Full Year and Fourth Quarter 2010 Financial and Operating Results
9. Regeneron to Webcast Investor Briefing on VEGF Trap-Eye Clinical Program on Sunday, February 13th at 9 am ET
10. Regeneron Announces Presentation at the ISI Annual Conference
11. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Pa. , Sept. 17, 2014  Fortune Oil ... officially changed its name to Manzo Pharmaceuticals, Inc. with ... to take effect today, September 17, 2014. Also taking ... The approval is a pivotal event in ... . Mr. Manzo explained, "We could not proceed with ...
(Date:9/17/2014)...  Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL ), ... received an unsolicited, non-binding proposal from Endo International plc ... the outstanding shares of Auxilium common stock at a ... stock, subject to due diligence, financing and other conditions. ... received from Endo on Friday evening is reproduced below. ...
(Date:9/17/2014)... 2014 Mindray (NYSE: MR)announced its new generation ... system has been showcased for the first time at ... September, and is scheduled for availability in the U.S. ... the most efficient workhorse in the mid-range segment, the ... perfectly optimized user experience including a gesture-sensitive touch screen, ...
Breaking Medicine Technology:Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 2Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 3Auxilium Responds To Unsolicited Proposal From Endo International 2Auxilium Responds To Unsolicited Proposal From Endo International 3Auxilium Responds To Unsolicited Proposal From Endo International 4Auxilium Responds To Unsolicited Proposal From Endo International 5Auxilium Responds To Unsolicited Proposal From Endo International 6Auxilium Responds To Unsolicited Proposal From Endo International 7Quality Exams at Your Fingertips 2
(Date:9/17/2014)... Oxford, UK, September 17, 2014 The International Journal ... has opened up its archive of previously published content: after ... read. A key aim of the IJS is ... hoped that by making these articles available to all will ... Editor-in-Chief of IJS said, "The journal has always ...
(Date:9/17/2014)... WA (PRWEB) September 17, 2014 A ... in fiscal year 2010 revealed 3.2% of these patients developed ... and 2.4% labeled as superficial SSIs. The average difference for ... 876, after adjustments. , The study, conducted by Marin Schweizer, ... the University of Iowa, found the treatment costs for the ...
(Date:9/17/2014)... September 17, 2014 The probability of ... with regular screening and examination, a healthy diet could ... of Epicure with the Chef MDs, renowned ... Paul Rusilko to prepare a delicious Fish Moilee. , ... diets that influence risk of prostate cancer, uncommonly found ...
(Date:9/17/2014)... Acceleratio Ltd., an innovative software development ... of Server Monitoring Toolkit , a web ... It brings real-time server monitoring via a live ... enhanced features that significantly improve troubleshooting and detection ... agentless data collection, a user-friendly interface, and many ...
(Date:9/17/2014)... September 17, 2014 Kamut International is ... a key ingredient in Michael Angelo’s new “Made With ... new fully organic lasagna ready made, frozen meal. Michael ... pastas and these new products align well with Kamut ... all KAMUT® Brand wheat must be grown certified organic. ...
Breaking Medicine News(10 mins):Health News:Three Ways to Minimize Costs Associated with Surgical Site Infections 2Health News:Boost Prostate Health with Epicure with the Chef MDs 2Health News:New Server Monitoring Toolkit v6 Brings Real-Time Windows Server Monitoring and New Server Reports 2Health News:New Server Monitoring Toolkit v6 Brings Real-Time Windows Server Monitoring and New Server Reports 3Health News:KAMUT® Brand Wheat Delivers a High Quality Ingredient and Authentic Italian Taste for Michael Angelo’s New Ready-Made Meals featuring Organic Ingredients 2
... A large-scale data review by researchers in China of ... the endoscopic procedure to be safe and effective for ... a pooled detection rate of 68.1 percent for all ... be the most common indication, with a relatively high ...
... cancer patients who use a new combination of the ... Gy) before surgery have an 88 percent chance of ... randomized trial presented at the plenary session, October 3, ... Society for Radiation Oncology (ASTRO). "The results of ...
... 2011) Researchers in Japan have completed a study showing ... pulp can be grafted and produce bone regeneration between parents ... of Cell Transplantation (20:7), now freely ... a number of reasons, and autogenous bone grafting - using ...
... , MONDAY, Sept. 26 (HealthDay News) -- ... inhibitor (SSRI) antidepressants and antiplatelet drugs such as aspirin ... those who take anti-clotting drugs only, a new study ... and Lexapro. Antiplatelet drugs prevent blood cells from ...
... the Witwatersrand goldfields, not far from bustling Johannesburg, South Africa, ... littered with mounds of waste and underlain by a deep ... with water. Today, the mines are producing less and less ... estimate the volume of acid mine drainage from abandoned mines ...
... Eating fruits and vegetables may reduce the risk of some ... examined the diets of 918 colorectal cancer patients and 1,021 ... consumption of certain vegetables and fruits were associated with a ... -- that is, the upper and lower portions of the ...
Cached Medicine News:Health News:Study examining large-scale data of double balloon enteroscopy shows it is safe and effective 2Health News:Study examining large-scale data of double balloon enteroscopy shows it is safe and effective 3Health News:Study examining large-scale data of double balloon enteroscopy shows it is safe and effective 4Health News:Chemo plus radiation before surgery increases tumor response for rectal cancer 2Health News:Cell Transplantation study shows bone growth from implanted tooth and dental pulp stem cells 2Health News:Certain Antidepressants With Blood Thinners May Pose Risk for Heart Patients 2Health News:Broccoli, Cabbage, Other Veggies May Protect Against Colon Cancer 2
The Flash MiniLabeler products can be configured to label microplates, tubes, vials, glass slides, circuit boards and a wide array of small products. Systems perform wrap around (tube or package) lab...
Shandon Laser MicroWriter is a laser labeling system developed specifically for anatomical pathology....
Modular Slide Storage Cabinet has a durable cold rolled steel construction with baked on epoxy finish. Drawers slide smoothly and quietly....
Store microscope slides with ease, speed, efficiency....
Medicine Products: